RE:Possible TR @450-days of 70%+I found this interesting statement in ImmunityBio's news release on their BCG-Unresponsive trial.
ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer ...
In addition, for patients with papillary disease, a disease-free survival rate at 18 months of 53%, which more than doubles the 25% rate published by the International Bladder Cancer Group as clinically meaningful So fair to assume that we already reach this IBCG target of 25%. And that we could surpass the "53%" of ImmunityBio. N-803 is used in combo with BCG. And its treatment is much complicated than ours:
Drug: N-803 and BCG (Phase 2) BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
Dr. Lerner went on to present results from the recent QUILT 3032 trial, where patients with NMIBC were randomized to 50 mgBCG plus 40 ug N-803 intravesically weekly x 6 induction or re-induction x6 with up to 2 years maintenance, with an option to extend. The 12 and 24 month durable complete remission in cohort A (CIS) was 60% and 52%, respectively. Note that our MSAB is Dr. Kamat. He's also the founder of IBCG. ... ;-)
In addition, for patients with papillary disease, a disease-free survival rate at 18 months of 53%, which more than doubles the 25% rate published by the International Bladder Cancer Group as clinically meaningful